Raymond W. Cohen

Mr. Cohen is an accredited public company director with over 35 years of experience in leading medical-device companies and serving as a board member at a number of private and publicly traded life science companies. From 2010 to 2012, he served as CEO of venture capital-backed Vessix Vascular, which was acquired by Boston Scientific in November 2012. He spent nearly a decade as Chairman and CEO of Nasdaq-listed Cardiac Science Inc., which was ranked as the fourth-fastest growing company in the US in 2004. Currently, Mr. Cohen serves as the Chairman of the board of directors at BioLife Solutions (Nasdaq: BLFS – preservation media for regenerative medicine) and as an independent director, Chair of the compensation committee and member of the audit and nominating committees of Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI – Oncology drugs). Mr. Cohen also served on the boards of two firms that successfully executed an exit transaction in 2017, Zurich-based LifeWatch (LIFE.SW), sold to Biotelemetry (Nasdaq: BEAT); and Westminster, CO-based, privately held Syncroness, Inc. (contract engineering), sold to ALTEN Group, a French multibillion-dollar engineering services company.